Will you offer capecitabine for 1 year to all localized TNBC patients?
Does the SYSUCC-001 trial presented at ASCO 2020 change your practice?
Answer from: Medical Oncologist at Academic Institution
The SYSUCC trial enrolled stage Ib-III TNBC patients who had either neoadjuvant or adjuvant systemic treatment followed by standard local therapy, and randomized the patients to either get 1 year of metronomic dosed capecitabine (650mg/m2 BID no break) x 12 months or observation. They observed an im...
Comments
Medical Oncologist at Oncology of NorthShore I generally agree with @Hatem H. Soliman's respons...
Medical Oncologist at Oncology of NorthShore One point further about the results in the stage I...
Medical Oncologist at Wisconsin Oncology @Hatem H. Soliman nicely summarized the important ...
I generally agree with @Hatem H. Soliman's respons...
One point further about the results in the stage I...
@Hatem H. Soliman nicely summarized the important ...